MDxHealth announces positive results on MGMT test.
The MGMT test has shown to be the only prognostic factor for overall survival in newly diagnosed glioblastoma multiforme (GBM) patients over the age of 70, the company added. A prognostic factor is a biological marker that helps determine the course and outcome of a disease. The results were published in the Journal of Clinical Oncology.
"This study confirms the results of a steadily increasing number of clinical trial reports that support the importance of MDxHealth's PredictMDx for Brain test in clinical decision making", CEO Jan Groen said.
|Printer friendly Cite/link Email Feedback|
|Publication:||ADP News Belgium|
|Date:||Jul 11, 2011|
|Previous Article:||Baronie to buy Barry Callebaut's European consumer arm.|
|Next Article:||Omega Pharma mulls over possible bourse exit.|